Sodium Iodide I 131
"The U.S. Food and Drug Administration today granted approval to Lenvima (lenvatinib) to treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine"...
Sodium Iodide I 131
The uptake of radioiodide will be affected by recent intake of stable iodine in any form, or by the use of thyroid, anti-thyroid and certain other drugs. Accordingly, the patient should be questioned carefully regarding previous medication and procedures involving radiographic contrast media.
The expiration date is not later than two months from the date of manufacture. The calibration date and the expiration date are stated on the container label.
As in the use of any radioactive material, care should be taken to minimize radiation exposure to the patient, consistent with proper patient management, and to insure minimum radiation exposure to occupational workers.
Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No long-term animal studies have been performed to evaluate carcinogenic potential, mutagenic potential, or whether this drug affects fertility in males or females.
Pregnancy Category C
Animal reproduction studies have not been conducted with Sodium Iodide I 131 (sodium iodide i 131 (sodium iodide i 131 capsules) capsules) Diagnostic Capsules. It is also not known whether Sodium Iodide I 131 (sodium iodide i 131 (sodium iodide i 131 capsules) capsules) Diagnostic Capsules can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Iodide I 131 (sodium iodide i 131 (sodium iodide i 131 capsules) capsules) Diagnostic Capsules should be given to a pregnant woman only if clearly needed.
Ideally, examinations using radiopharmaceutical drug products – especially those elective in nature – of women of childbearing capability should be performed during the first ten days following the onset of menses.
Safety and effectiveness in pediatric patients have not been established.
Last reviewed on RxList: 5/19/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Sodium Iodide I 131 Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.